Literature DB >> 19155086

Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests.

Marta I Minervini1, Kristine Ruppert, Paulo Fontes, Riccardo Volpes, Giovanni Vizzini, Michael E de Vera, Salvatore Gruttadauria, Roberto Miraglia, Loredana Pipitone, J Wallis Marsh, Amadeo Marcos, Bruno Gridelli, Anthony J Demetris.   

Abstract

BACKGROUND/AIMS: Liver biopsies detect silent donor disease in potential living liver donors and provide material for studies of subclinical non-alcoholic fatty liver disease (NAFLD). Our primary goal was to determine the contribution of biopsy findings to potential donor evaluation. Factors contributing to pre-clinical NAFLD and correlations between liver injury tests and histopathology have been also determined.
METHODS: Patient records, laboratory tests and results of the histopathologic examination and diagnoses of 284 patients from 2001 to 2005 were retrospectively extracted from the EDIT database. Hepatic histology was correlated with liver injury tests and with general demographic characteristics in an otherwise normal healthy population.
RESULTS: A minority (n=119; 42%) of biopsies from this population of 143 males/141 females (average age=36.8years; mean BMI=26.6) were completely normal. The remainder showed steatosis (n=107; 37%), steatohepatitis (n=44; 15%), or unexplained low-grade/early stage chronic hepatitis, primary biliary cirrhosis, or nodular regenerative hyperplasia (n=16; 6%). Biopsy findings disqualified 29/56 donors. Independent risk factors for NAFLD by multivariate modeling, which differed by sex, included: BMI (p=0.0001), age (p=0.003), iron (p=0.01), and ALT (p=0.004).
CONCLUSIONS: Liver biopsies provide valuable information about otherwise undetectable liver disease in potential liver donors. Obesity, age and iron, which are influenced by sex, contribute to NAFLD pathogenesis. Blood tests other than standard liver profiles are needed to detect early NAFLD.

Entities:  

Mesh:

Year:  2008        PMID: 19155086     DOI: 10.1016/j.jhep.2008.10.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.

Authors:  Ruben Hernaez; Jody McLean; Mariana Lazo; Frederick L Brancati; Joel N Hirschhorn; Ingrid B Borecki; Tamara B Harris; Thutrang Nguyen; Ihab R Kamel; Susanne Bonekamp; Mark S Eberhardt; Jeanne M Clark; Wen Hong Linda Kao; Elizabeth K Speliotes
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-13       Impact factor: 11.382

Review 2.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

3.  Pentoxifylline for steatohepatitis: magic bullet or smoking gun?

Authors:  Richard K Sterling; Arun J Sanyal
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

4.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

Review 5.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

6.  Shear wave dispersion measures liver steatosis.

Authors:  Christopher T Barry; Bradley Mills; Zaegyoo Hah; Robert A Mooney; Charlotte K Ryan; Deborah J Rubens; Kevin J Parker
Journal:  Ultrasound Med Biol       Date:  2011-12-16       Impact factor: 2.998

7.  Human germline hedgehog pathway mutations predispose to fatty liver.

Authors:  Maria J Guillen-Sacoto; Ariel F Martinez; Yu Abe; Paul Kruszka; Karin Weiss; Joshua L Everson; Ramon Bataller; David E Kleiner; Jerrold M Ward; Kathleen K Sulik; Robert J Lipinski; Benjamin D Solomon; Maximilian Muenke
Journal:  J Hepatol       Date:  2017-06-21       Impact factor: 25.083

Review 8.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Neven Baršić; Ivan Lerotić; Lea Smirčić-Duvnjak; Vedran Tomašić; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

Review 9.  The genetics of NAFLD.

Authors:  Quentin M Anstee; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802

Review 10.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.